Comparative Pharmacology
Head-to-head clinical analysis: BETAMETHASONE VALERATE versus BREO ELLIPTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAMETHASONE VALERATE versus BREO ELLIPTA.
BETAMETHASONE VALERATE vs BREO ELLIPTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betamethasone valerate is a corticosteroid that binds to the glucocorticoid receptor, leading to increased synthesis of lipocortin, which inhibits phospholipase A2 and reduces arachidonic acid release, thereby decreasing prostaglandin and leukotriene production. It also suppresses cytokine expression and inflammatory cell migration.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Apply a thin film to affected area twice daily. Maximum 15 g/day for 2 weeks.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
None Documented
None Documented
Terminal elimination half-life is approximately 36–54 hours for the parent drug after topical application; systemic absorption is low. For oral or IV administration, the half-life is about 3–5 hours, but clinical effects persist longer due to receptor-mediated mechanisms.
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Renal (primarily as metabolites, unchanged drug <5%). Biliary/fecal elimination accounts for a minor fraction. Essentially no significant renal excretion of active drug.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Category D/X
Category C
Corticosteroid
Corticosteroid/Beta-2 Agonist Combination